$117
Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $117.20 – an increase of 0.62% over the previous week. Novo Nordisk A/S employs 69,260 staff and has a trailing 12-month revenue of around $258 billion.
What's in this guide?
- NVO shares summary
- Compare share dealing platforms
- Is NVO stock a buy or sell?
- Stock performance over time
- Can I short NVO shares?
- Are NVO shares over-valued?
- Novo Nordisk A/S's financials
- How volatile are NVO shares?
- Does Novo Nordisk A/S pay a dividend?
- Have NVO shares ever split?
- Other common questions
Our top picks for where to buy Novo Nordisk A/S stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
How to buy Novo Nordisk A/S stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NVO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Novo Nordisk A/S stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Novo Nordisk A/S stock price (NYSE: NVO)
Use our graph to track the performance of NVO stocks over time.Novo Nordisk A/S shares at a glance
Latest market close | $117.20 |
---|---|
52-week range | $91.93 - $147.59 |
50-day moving average | $129.95 |
200-day moving average | $127.32 |
Wall St. target price | $142.97 |
PE ratio | 39.7288 |
Dividend yield | $9.9 (1.23%) |
Earnings per share (TTM) | $2.95 |
Is it a good time to buy Novo Nordisk A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Novo Nordisk A/S price performance over time
Historical closes compared with the close of $117.2 from 2024-10-08
1 week (2024-10-03) | 1.84% |
---|---|
1 month (2024-09-10) | -9.69% |
3 months (2024-07-10) | -17.89% |
6 months (2024-04-10) | -6.19% |
1 year (2023-10-10) | 26.01% |
---|---|
2 years (2022-10-10) | 12.86% |
3 years (2021-10-08) | 19.13% |
5 years (2019-10-10) | 136.47% |
Is Novo Nordisk A/S stock undervalued or overvalued?
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novo Nordisk A/S's P/E ratio
Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Novo Nordisk A/S shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novo Nordisk A/S's PEG ratio
Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7905. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novo Nordisk A/S's EBITDA
Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $126.6 billion.
The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.
Novo Nordisk A/S financials
Revenue TTM | $258 billion |
---|---|
Operating margin TTM | 46.48% |
Gross profit TTM | $148.5 billion |
Return on assets TTM | 22.8% |
Return on equity TTM | 88.57% |
Profit margin | 34.84% |
Book value | $25.24 |
Market Capitalization | $522.1 billion |
TTM: trailing 12 months
Novo Nordisk A/S share dividends
Dividend payout ratio: 49.36% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 49.36% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.23% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.23% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $9.9 per share.
While Novo Nordisk A/S's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk A/S may be investing much of the rest of its net profits in future growth.
Novo Nordisk A/S's most recent dividend payout was on 25 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 15 August 2024 (the "ex-dividend date").
Have Novo Nordisk A/S's shares ever split?
Novo Nordisk A/S's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Novo Nordisk A/S share price volatility
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $91.928 up to $147.5933. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.148. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc.
Frequently asked questions
nullWhat percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.004% of Novo Nordisk A/S shares are held by insiders and 10.203% by institutions. How many people work for Novo Nordisk A/S?
Latest data suggests 69,260 work at Novo Nordisk A/S. When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December. Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Alle 1, Bagsvaerd, Denmark, 2880 What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056 What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question